FI3030557T3 - Uusia ftalatsinonijohdannaisia ja niiden valmistusmenetelmä - Google Patents
Uusia ftalatsinonijohdannaisia ja niiden valmistusmenetelmä Download PDFInfo
- Publication number
- FI3030557T3 FI3030557T3 FIEP14843941.7T FI14843941T FI3030557T3 FI 3030557 T3 FI3030557 T3 FI 3030557T3 FI 14843941 T FI14843941 T FI 14843941T FI 3030557 T3 FI3030557 T3 FI 3030557T3
- Authority
- FI
- Finland
- Prior art keywords
- carbonyl
- azetidine
- phthalazin
- compound
- fluorobenzyl
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 45
- 150000002431 hydrogen Chemical class 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 3
- -1 methylene, carbonyl Chemical group 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- KKSZOZGTFLMQIZ-UHFFFAOYSA-N C1(CC1)CNC1CN(C1)C(=O)C=1C=C(CC2=NNC(C3=CC=CC=C23)=O)C=CC1F Chemical compound C1(CC1)CNC1CN(C1)C(=O)C=1C=C(CC2=NNC(C3=CC=CC=C23)=O)C=CC1F KKSZOZGTFLMQIZ-UHFFFAOYSA-N 0.000 claims 2
- DKJMZXNQISEHFU-UHFFFAOYSA-N C1(CC1)CNCC1CN(C1)C(=O)C=1C=C(CC2=NNC(C3=CC=CC=C23)=O)C=CC1F Chemical compound C1(CC1)CNCC1CN(C1)C(=O)C=1C=C(CC2=NNC(C3=CC=CC=C23)=O)C=CC1F DKJMZXNQISEHFU-UHFFFAOYSA-N 0.000 claims 2
- GKUXCCVQBLJTMD-MRXNPFEDSA-N C1(CC1)N[C@H]1CN(CC1)C(=O)C=1C=C(CC2=NNC(C3=CC=CC=C23)=O)C=CC1F Chemical compound C1(CC1)N[C@H]1CN(CC1)C(=O)C=1C=C(CC2=NNC(C3=CC=CC=C23)=O)C=CC1F GKUXCCVQBLJTMD-MRXNPFEDSA-N 0.000 claims 2
- XESQDDBWEOEUDO-UHFFFAOYSA-N C1(CCC1)NCC1CN(C1)C(=O)C=1C=C(CC2=NNC(C3=CC=CC=C23)=O)C=CC1F Chemical compound C1(CCC1)NCC1CN(C1)C(=O)C=1C=C(CC2=NNC(C3=CC=CC=C23)=O)C=CC1F XESQDDBWEOEUDO-UHFFFAOYSA-N 0.000 claims 2
- XZUMNWIZCNUMAS-GOSISDBHSA-N C1(CCCC1)N[C@H]1CN(CC1)C(=O)C=1C=C(CC2=NNC(C3=CC=CC=C23)=O)C=CC1F Chemical compound C1(CCCC1)N[C@H]1CN(CC1)C(=O)C=1C=C(CC2=NNC(C3=CC=CC=C23)=O)C=CC1F XZUMNWIZCNUMAS-GOSISDBHSA-N 0.000 claims 2
- IGINPWSVDNTKOK-UHFFFAOYSA-N Cl.C1(CC1)CNC1CN(C1)C(=O)C=1C=C(CC2=NNC(C3=CC=CC=C23)=O)C=CC1F Chemical compound Cl.C1(CC1)CNC1CN(C1)C(=O)C=1C=C(CC2=NNC(C3=CC=CC=C23)=O)C=CC1F IGINPWSVDNTKOK-UHFFFAOYSA-N 0.000 claims 2
- PNQARVCRZIKCHP-UHFFFAOYSA-N Cl.C1(CC1)CNCC1CN(C1)C(=O)C=1C=C(CC2=NNC(C3=CC=CC=C23)=O)C=CC1F Chemical compound Cl.C1(CC1)CNCC1CN(C1)C(=O)C=1C=C(CC2=NNC(C3=CC=CC=C23)=O)C=CC1F PNQARVCRZIKCHP-UHFFFAOYSA-N 0.000 claims 2
- FSVSACOGQQIXAF-UHFFFAOYSA-N Cl.C1(CC1)NCC1CN(C1)C(=O)C=1C=C(CC2=NNC(C3=CC=CC=C23)=O)C=CC1F Chemical compound Cl.C1(CC1)NCC1CN(C1)C(=O)C=1C=C(CC2=NNC(C3=CC=CC=C23)=O)C=CC1F FSVSACOGQQIXAF-UHFFFAOYSA-N 0.000 claims 2
- UBSLSGKRSOQQKE-UHFFFAOYSA-N Cl.C1(CCC1)NCC1CN(C1)C(=O)C=1C=C(CC2=NNC(C3=CC=CC=C23)=O)C=CC1F Chemical compound Cl.C1(CCC1)NCC1CN(C1)C(=O)C=1C=C(CC2=NNC(C3=CC=CC=C23)=O)C=CC1F UBSLSGKRSOQQKE-UHFFFAOYSA-N 0.000 claims 2
- OSXBCQJXDXZASP-UHFFFAOYSA-N Cl.C1(CCCC1)NC1CN(C1)C(=O)C=1C=C(CC2=NNC(C3=CC=CC=C23)=O)C=CC1F Chemical compound Cl.C1(CCCC1)NC1CN(C1)C(=O)C=1C=C(CC2=NNC(C3=CC=CC=C23)=O)C=CC1F OSXBCQJXDXZASP-UHFFFAOYSA-N 0.000 claims 2
- HPHLEONXLLWYKF-UHFFFAOYSA-N Cl.FC1=C(C=C(CC2=NNC(C3=CC=CC=C23)=O)C=C1)C(=O)N1CC(C1)CNC(C)C Chemical compound Cl.FC1=C(C=C(CC2=NNC(C3=CC=CC=C23)=O)C=C1)C(=O)N1CC(C1)CNC(C)C HPHLEONXLLWYKF-UHFFFAOYSA-N 0.000 claims 2
- KTJXLDNKRDIIKT-UHFFFAOYSA-N Cl.FC1=C(C=C(CC2=NNC(C3=CC=CC=C23)=O)C=C1)C(=O)N1CC(C1)NC(C)C Chemical compound Cl.FC1=C(C=C(CC2=NNC(C3=CC=CC=C23)=O)C=C1)C(=O)N1CC(C1)NC(C)C KTJXLDNKRDIIKT-UHFFFAOYSA-N 0.000 claims 2
- HQGFJTPHAXRFJN-UHFFFAOYSA-N Cl.FC1=C(C=C(CC2=NNC(C3=CC=CC=C23)=O)C=C1)C(=O)N1CC(C1)NCC(C)C Chemical compound Cl.FC1=C(C=C(CC2=NNC(C3=CC=CC=C23)=O)C=C1)C(=O)N1CC(C1)NCC(C)C HQGFJTPHAXRFJN-UHFFFAOYSA-N 0.000 claims 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical group CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 claims 2
- LWCQZYNHAVNPAH-UHFFFAOYSA-N FC1=C(C=C(CC2=NNC(C3=CC=CC=C23)=O)C=C1)C(=O)N1CC(C1)CNC(C)C Chemical compound FC1=C(C=C(CC2=NNC(C3=CC=CC=C23)=O)C=C1)C(=O)N1CC(C1)CNC(C)C LWCQZYNHAVNPAH-UHFFFAOYSA-N 0.000 claims 2
- JFCUZMQKURGQOK-UHFFFAOYSA-N FC1=C(C=C(CC2=NNC(C3=CC=CC=C23)=O)C=C1)C(=O)N1CC(C1)NC(C)C Chemical compound FC1=C(C=C(CC2=NNC(C3=CC=CC=C23)=O)C=C1)C(=O)N1CC(C1)NC(C)C JFCUZMQKURGQOK-UHFFFAOYSA-N 0.000 claims 2
- DSBIAGOLCXYHPB-UHFFFAOYSA-N FC1=C(C=C(CC2=NNC(C3=CC=CC=C23)=O)C=C1)C(=O)N1CC(C1)NCC(C)C Chemical compound FC1=C(C=C(CC2=NNC(C3=CC=CC=C23)=O)C=C1)C(=O)N1CC(C1)NCC(C)C DSBIAGOLCXYHPB-UHFFFAOYSA-N 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- YNBQAYKYNYRCCA-UHFFFAOYSA-N venadaparib Chemical compound C1(CC1)NCC1CN(C1)C(=O)C=1C=C(CC2=NNC(C3=CC=CC=C23)=O)C=CC1F YNBQAYKYNYRCCA-UHFFFAOYSA-N 0.000 claims 2
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 claims 1
- OOGCIODHIGNQIQ-UHFFFAOYSA-N 4-[[4-fluoro-3-[3-[[1-(trifluoromethyl)cyclopropyl]amino]azetidine-1-carbonyl]phenyl]methyl]-2h-phthalazin-1-one Chemical compound FC1=CC=C(CC=2C3=CC=CC=C3C(=O)NN=2)C=C1C(=O)N(C1)CC1NC1(C(F)(F)F)CC1 OOGCIODHIGNQIQ-UHFFFAOYSA-N 0.000 claims 1
- 108700020463 BRCA1 Proteins 0.000 claims 1
- 102000036365 BRCA1 Human genes 0.000 claims 1
- 101150072950 BRCA1 gene Proteins 0.000 claims 1
- 108700020462 BRCA2 Proteins 0.000 claims 1
- 102000052609 BRCA2 Human genes 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 101150008921 Brca2 gene Proteins 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- YCAPBAODPGKNAI-UHFFFAOYSA-N C1(CCCC1)NC1CN(C1)C(=O)C=1C=C(CC2=NNC(C3=CC=CC=C23)=O)C=CC1F Chemical compound C1(CCCC1)NC1CN(C1)C(=O)C=1C=C(CC2=NNC(C3=CC=CC=C23)=O)C=CC1F YCAPBAODPGKNAI-UHFFFAOYSA-N 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- 101001077417 Gallus gallus Potassium voltage-gated channel subfamily H member 6 Proteins 0.000 claims 1
- 101001010792 Homo sapiens Transcriptional regulator ERG Proteins 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 102100022807 Potassium voltage-gated channel subfamily H member 2 Human genes 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 230000007547 defect Effects 0.000 claims 1
- QKIUAMUSENSFQQ-UHFFFAOYSA-N dimethylazanide Chemical group C[N-]C QKIUAMUSENSFQQ-UHFFFAOYSA-N 0.000 claims 1
- 125000004494 ethyl ester group Chemical group 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical group 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20130110170 | 2013-09-13 | ||
| KR1020140120152A KR101670126B1 (ko) | 2013-09-13 | 2014-09-11 | 신규 프탈라지논 유도체 및 그 제조방법 |
| PCT/KR2014/008523 WO2015037939A1 (en) | 2013-09-13 | 2014-09-12 | A novel phtalazinone derivatives and manufacturing process thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3030557T3 true FI3030557T3 (fi) | 2023-08-21 |
Family
ID=53024930
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP14843941.7T FI3030557T3 (fi) | 2013-09-13 | 2014-09-12 | Uusia ftalatsinonijohdannaisia ja niiden valmistusmenetelmä |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US9682973B2 (OSRAM) |
| EP (1) | EP3030557B1 (OSRAM) |
| JP (1) | JP6180643B2 (OSRAM) |
| KR (1) | KR101670126B1 (OSRAM) |
| CN (1) | CN105793248B (OSRAM) |
| AU (1) | AU2014319132C1 (OSRAM) |
| BR (1) | BR112016004979B1 (OSRAM) |
| CA (1) | CA2923614C (OSRAM) |
| DK (1) | DK3030557T3 (OSRAM) |
| ES (1) | ES2953834T3 (OSRAM) |
| FI (1) | FI3030557T3 (OSRAM) |
| HR (1) | HRP20230998T1 (OSRAM) |
| HU (1) | HUE062770T2 (OSRAM) |
| IL (1) | IL244548B (OSRAM) |
| LT (1) | LT3030557T (OSRAM) |
| MX (1) | MX379467B (OSRAM) |
| MY (1) | MY195343A (OSRAM) |
| PL (1) | PL3030557T3 (OSRAM) |
| PT (1) | PT3030557T (OSRAM) |
| RS (1) | RS64477B1 (OSRAM) |
| RU (1) | RU2636585C2 (OSRAM) |
| SG (1) | SG11201600549TA (OSRAM) |
| SI (1) | SI3030557T1 (OSRAM) |
| SM (1) | SMT202300268T1 (OSRAM) |
| WO (1) | WO2015037939A1 (OSRAM) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101670126B1 (ko) * | 2013-09-13 | 2016-10-27 | 일동제약(주) | 신규 프탈라지논 유도체 및 그 제조방법 |
| US11542282B2 (en) | 2018-02-28 | 2023-01-03 | The Trustees Of The University Of Pennsylvania | Low affinity poly(AD-ribose) polymerase 1 dependent cytotoxic agents |
| BR112022021321A2 (pt) * | 2020-04-21 | 2022-12-20 | Idience Co Ltd | Formas cristalinas do composto de ftalazinona. |
| US12060345B2 (en) | 2020-04-21 | 2024-08-13 | Idience Co., Ltd. | Process for preparing a phthalazinone derivative and intermediates thereof |
| EP4148046A4 (en) * | 2020-05-08 | 2024-07-24 | Txinno Bioscience Inc. | NEW PHTHALAZINE DERIVATIVE WITH ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE INHIBITING ACTIVITY AND USE THEREOF |
| US12059419B2 (en) * | 2020-10-16 | 2024-08-13 | Idience Co., Ltd. | Pharmaceutical composition comprising phthalazinone derivatives |
| US20230391752A1 (en) * | 2020-10-22 | 2023-12-07 | Chulalongkorn University | Pyrrolidine-3-carboxamide derivatives and related uses |
| KR20220125183A (ko) | 2021-03-04 | 2022-09-14 | 아이디언스 주식회사 | Parp 억제제에 내성을 가진 환자군의 암 치료제로서의 프탈라지논 유도체의 항암제 용도 |
| WO2022186649A1 (ko) * | 2021-03-04 | 2022-09-09 | 아이디언스 주식회사 | Parp 억제제에 내성을 가진 환자군의 암 치료제로서의 프탈라지논 유도체의 항암제 용도 |
| TW202313040A (zh) * | 2021-06-02 | 2023-04-01 | 南韓商愛迪恩斯股份有限公司 | 以酞嗪酮衍生物治療病症的方法 |
| WO2023144626A1 (en) * | 2022-01-25 | 2023-08-03 | Idience Co., Ltd. | Pharmaceutical composition including phthalazinone derivative for co-administration with anticancer drug |
| WO2024025389A1 (ko) * | 2022-07-29 | 2024-02-01 | 아이디언스 주식회사 | 프탈라지논 유도체의 중간체의 제조방법 |
| CN117229260B (zh) * | 2023-11-13 | 2024-02-27 | 中国药科大学 | DNA聚合酶θ与聚ADP核糖聚合酶1双靶点抑制剂及其制备方法和医药用途 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2384776C (en) | 2000-10-30 | 2006-02-03 | Kudos Pharm Ltd | Phthalazinone derivatives |
| ES2357057T3 (es) | 2002-04-30 | 2011-04-15 | Kudos Pharmaceuticals Limited | Derivados de ftalazinona. |
| US7449464B2 (en) | 2003-03-12 | 2008-11-11 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
| KR101146806B1 (ko) | 2003-03-12 | 2012-05-22 | 메이브릿지 리미티드 | 프탈라지논 유도체 |
| AU2007266840B2 (en) | 2006-05-31 | 2012-09-20 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Pyrrolo[1,2-A]pyrazin-1(2H)-one and pyrrolo[1,2-D][1,2,4]triazin-1(2H)-one derivatives as inhibitors of poly(ADP-ribose)polymerase(PARP) |
| GB0610680D0 (en) | 2006-05-31 | 2006-07-12 | Istituto Di Ricerche D Biolog | Therapeutic compounds |
| SI2698062T1 (sl) | 2006-12-28 | 2015-12-31 | Abbvie Inc. | Inhibitorji poli (ADP-riboza) polimeraze |
| CN101030723A (zh) | 2007-04-04 | 2007-09-05 | 钟志华 | 电磁变相发动机 |
| ES2524787T3 (es) | 2007-11-15 | 2014-12-12 | Msd Italia S.R.L. | Derivados de piridazinona como inhibidores de PARP |
| UY31603A1 (es) * | 2008-01-23 | 2009-08-31 | Derivados de ftalazinona | |
| GB0804755D0 (en) | 2008-03-14 | 2008-04-16 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| EP2598491B1 (en) | 2010-07-27 | 2015-09-02 | Cadila Healthcare Limited | Substituted 4-(4-fluoro-3-(piperazine-1- carbonyl)benzyl)phthalazin-1(2h)-one derivatives as poly (adp-ribose) polymerase- 1 inhibitors |
| CN102372706A (zh) * | 2010-08-09 | 2012-03-14 | 江苏恒瑞医药股份有限公司 | 酞嗪酮类衍生物、其制备方法及其在医药上的应用 |
| CN102372716A (zh) | 2010-08-09 | 2012-03-14 | 江苏恒瑞医药股份有限公司 | 酞嗪酮类衍生物、其制备方法及其在医药上的应用 |
| CN102372698A (zh) | 2010-08-10 | 2012-03-14 | 江苏恒瑞医药股份有限公司 | 酞嗪酮类衍生物、其制备方法及其在医药上的应用 |
| ES2590682T3 (es) * | 2010-12-02 | 2016-11-23 | Shanghai De Novo Pharmatech Co Ltd. | Derivados heterocíclicos, procesos de preparación y usos médicos de los mismos |
| CN102485721B (zh) | 2010-12-03 | 2015-12-09 | 曹亚 | 取代的2,3-二氮杂萘酮化合物及其用途 |
| CN103130723B (zh) | 2011-11-30 | 2015-01-14 | 成都地奥制药集团有限公司 | 一种多聚(adp-核糖)聚合酶抑制剂 |
| KR101670126B1 (ko) * | 2013-09-13 | 2016-10-27 | 일동제약(주) | 신규 프탈라지논 유도체 및 그 제조방법 |
-
2014
- 2014-09-11 KR KR1020140120152A patent/KR101670126B1/ko active Active
- 2014-09-12 SG SG11201600549TA patent/SG11201600549TA/en unknown
- 2014-09-12 CN CN201480049174.5A patent/CN105793248B/zh active Active
- 2014-09-12 FI FIEP14843941.7T patent/FI3030557T3/fi active
- 2014-09-12 US US15/021,336 patent/US9682973B2/en active Active
- 2014-09-12 HR HRP20230998TT patent/HRP20230998T1/hr unknown
- 2014-09-12 BR BR112016004979-9A patent/BR112016004979B1/pt active IP Right Grant
- 2014-09-12 DK DK14843941.7T patent/DK3030557T3/da active
- 2014-09-12 PT PT148439417T patent/PT3030557T/pt unknown
- 2014-09-12 SI SI201432038T patent/SI3030557T1/sl unknown
- 2014-09-12 SM SM20230268T patent/SMT202300268T1/it unknown
- 2014-09-12 RU RU2016108038A patent/RU2636585C2/ru active
- 2014-09-12 HU HUE14843941A patent/HUE062770T2/hu unknown
- 2014-09-12 CA CA2923614A patent/CA2923614C/en active Active
- 2014-09-12 AU AU2014319132A patent/AU2014319132C1/en active Active
- 2014-09-12 US US16/447,174 patent/USRE49338E1/en active Active
- 2014-09-12 RS RS20230721A patent/RS64477B1/sr unknown
- 2014-09-12 EP EP14843941.7A patent/EP3030557B1/en active Active
- 2014-09-12 MY MYPI2016700730A patent/MY195343A/en unknown
- 2014-09-12 LT LTEPPCT/KR2014/008523T patent/LT3030557T/lt unknown
- 2014-09-12 WO PCT/KR2014/008523 patent/WO2015037939A1/en not_active Ceased
- 2014-09-12 MX MX2016002998A patent/MX379467B/es unknown
- 2014-09-12 PL PL14843941.7T patent/PL3030557T3/pl unknown
- 2014-09-12 ES ES14843941T patent/ES2953834T3/es active Active
- 2014-09-12 JP JP2016542643A patent/JP6180643B2/ja active Active
-
2016
- 2016-03-11 IL IL244548A patent/IL244548B/en active IP Right Grant
-
2017
- 2017-03-10 US US15/455,631 patent/US9844550B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3030557T3 (fi) | Uusia ftalatsinonijohdannaisia ja niiden valmistusmenetelmä | |
| EA201992126A1 (ru) | Ингибиторы jak, содержащие 4-членный гетероциклический амид | |
| MY206521A (en) | Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof | |
| NZ630205A (en) | Enhancer of zeste homolog 2 inhibitors | |
| BR112018008714A2 (pt) | inibidores de isoindolina, azaisoindolina, dihidroindenona e dihidroazaindenona da mnk1 e mnk2 | |
| CN106660974A (zh) | 含氨磺酰基的1,2,5‑噁二唑类衍生物、其制备方法及其在医药上的应用 | |
| HK1245260A1 (zh) | 细胞周期蛋白依赖性激酶7(cdk7)的抑制剂 | |
| JO3377B1 (ar) | مشتقات بيريدينيل وبيريدينيل مندمج | |
| EA202090987A1 (ru) | Новые пролекарства на основе катехоламина для применения в лечении болезни паркинсона | |
| EA201591291A1 (ru) | Производные пиримидона и их применение в лечении, облегчении или профилактике вирусного заболевания | |
| PH12015500457A1 (en) | Alkoxy pyrazoles as soluble guanylate cyclase activators | |
| PL415078A1 (pl) | Podstawione aminotriazole przydatne jako inhibitory kwaśnej chitynazy ssaków | |
| PH12014500326B1 (en) | Heterocyclic derivative and pharmaceutical drug | |
| NZ712180A (en) | Pyridazinone compounds and methods for the treatment of cystic fibrosis | |
| EA201391486A1 (ru) | Способы и композиции для лечения болезни паркинсона | |
| PH12019550083A1 (en) | Inhibitors of bruton's tyrosine kinase | |
| RU2016122731A (ru) | Функционализированные и замещенные индолы в качестве противораковых агентов | |
| JP2014518544A5 (OSRAM) | ||
| MX377202B (es) | Derivado basado en 1,2-naftoquinona y metodo de preparacion del mismo. | |
| PH12015500063B1 (en) | Azaindole derivatives which act as pi3k inhibitors | |
| MX2016014574A (es) | El uso de compuestos de tienotriazolodiazepina para el tratamiento de cancer de mama triple-negativo. | |
| EA201692557A1 (ru) | Хинолизиноновые производные в качестве ингибиторов pi3k | |
| EA201891682A1 (ru) | Производное азациклического амида, способ его получения и фармацевтическое применение | |
| JP2014524449A5 (OSRAM) | ||
| PH12017501750A1 (en) | 6-morpholinyl-2-pyrazolyl-9h-purine derivatives and their use as pi3k inhibitors |